Jun 30, 2024

Bausch Health Q2 2024 Earnings Report

Bausch Health announced its second quarter results, showcasing revenue and adjusted EBITDA growth and raised full-year guidance.

Key Takeaways

Bausch Health reported a strong second quarter with an 11% increase in consolidated revenues to $2.40 billion and a 10% increase in adjusted EBITDA to $798 million. The company also raised its full-year revenue and adjusted EBITDA guidance, reflecting confidence in its growth strategy and product portfolio.

Consolidated revenues reached $2.40 billion, up 11% year-over-year.

Adjusted EBITDA increased by 10% to $798 million.

GAAP Net Income Attributable to Bausch Health Companies Inc. was $10 million.

Full-year revenue and Adjusted EBITDA guidance were raised.

Total Revenue
$2.4B
Previous year: $2.17B
+10.9%
EPS
$0.98
Previous year: $0.81
+21.0%
Adjusted EBITDA
$798M
Previous year: $727M
+9.8%
Gross Profit
$1.41B
Previous year: $1.52B
-6.9%
Cash and Equivalents
$595M
Previous year: $588M
+1.2%
Free Cash Flow
$302M
Previous year: $178M
+69.7%
Total Assets
$26.5B
Previous year: $25.5B
+3.9%

Bausch Health

Bausch Health

Bausch Health Revenue by Segment

Forward Guidance

The Company raised its consolidated full-year Revenue guidance to $9.400 - $9.650 billion and Adjusted EBITDA guidance to $3.21 - $3.36 billion.

Positive Outlook

  • Revenue (in Billions): $9.400 - $9.650
  • BHC (excl. B+L) Revenue (in Billions): $4.700 - $4.850
  • B+L Revenue (in Billions): $4.700 - $4.800
  • Organic growth vs. Prior Year: 2%-5%
  • Adjusted EBITDA (in Billions): $3.21 - $3.36

Revenue & Expenses

Visualization of income flow from segment revenue to net income